39273625|t|A Novel Rare PSEN2 Val226Ala in PSEN2 in a Korean Patient with Atypical Alzheimer's Disease, and the Importance of PSEN2 5th Transmembrane Domain (TM5) in AD Pathogenesis.
39273625|a|In this manuscript, a novel presenilin-2 (PSEN2) mutation, Val226Ala, was found in a 59-year-old Korean patient who exhibited rapid progressive memory dysfunction and hallucinations six months prior to her first visit to the hospital. Her Magnetic Resonance Imaging (MRI) showed brain atrophy, and both amyloid positron emission tomography (PET) and multimer detection system-oligomeric amyloid-beta (Abeta) results were positive. The patient was diagnosed with early onset Alzheimer's disease. The whole-exome analysis revealed a new PSEN2 Val226Ala mutation with heterozygosity in the 5th transmembrane domain of the PSEN2 protein near the lumen region. Analyses of the structural prediction suggested structural changes in the helix, specifically a loss of a hydrogen bond between Val226 and Gln229, which may lead to elevated helix motion. Multiple PSEN2 mutations were reported in PSEN2 transmembrane-5 (TM5), such as Tyr231Cys, Ile235Phe, Ala237Val, Leu238Phe, Leu238Pro, and Met239Thr, highlighting the dynamic importance of the 5th transmembrane domain of PSEN2. Mutations in TM5 may alter the access tunnel of the Abeta substrate in the membrane to the gamma-secretase active site, indicating a possible influence on enzyme function that increases Abeta production. Interestingly, the current patient with the Val226Ala mutation presented with a combination of hallucinations and memory dysfunction. Although the causal mechanisms of hallucinations in AD remain unclear, it is possible that PSEN2 interacts with other disease risk factors, including Notch Receptor 3 (NOTCH3) or Glucosylceramidase Beta-1 (GBA) variants, enhancing the occurrence of hallucinations. In conclusion, the direct or indirect role of PSEN2 Val226Ala in AD onset cannot be ruled out.
39273625	13	18	PSEN2	Gene	5664
39273625	19	28	Val226Ala	ProteinMutation	tmVar:p|SUB|V|226|A;HGVS:p.V226A;VariantGroup:3;CorrespondingGene:5664;RS#:1408884573;CorrespondingSpecies:9606
39273625	32	37	PSEN2	Gene	5664
39273625	50	57	Patient	Species	9606
39273625	72	91	Alzheimer's Disease	Disease	MESH:D000544
39273625	115	120	PSEN2	Gene	5664
39273625	155	157	AD	Disease	MESH:D000544
39273625	200	212	presenilin-2	Gene	5664
39273625	214	219	PSEN2	Gene	5664
39273625	231	240	Val226Ala	ProteinMutation	tmVar:p|SUB|V|226|A;HGVS:p.V226A;VariantGroup:3;CorrespondingGene:5664;RS#:1408884573;CorrespondingSpecies:9606
39273625	276	283	patient	Species	9606
39273625	316	334	memory dysfunction	Disease	MESH:D008569
39273625	339	353	hallucinations	Disease	MESH:D006212
39273625	451	464	brain atrophy	Disease	MESH:C566985
39273625	559	571	amyloid-beta	Gene	351
39273625	573	578	Abeta	Gene	351
39273625	607	614	patient	Species	9606
39273625	646	665	Alzheimer's disease	Disease	MESH:D000544
39273625	707	712	PSEN2	Gene	5664
39273625	713	722	Val226Ala	ProteinMutation	tmVar:p|SUB|V|226|A;HGVS:p.V226A;VariantGroup:3;CorrespondingGene:5664;RS#:1408884573;CorrespondingSpecies:9606
39273625	791	796	PSEN2	Gene	5664
39273625	956	962	Val226	ProteinMutation	tmVar:p|Allele|V|226;VariantGroup:3;CorrespondingGene:5664;RS#:1408884573;CorrespondingSpecies:9606
39273625	1025	1030	PSEN2	Gene	5664
39273625	1095	1104	Tyr231Cys	ProteinMutation	tmVar:p|SUB|Y|231|C;HGVS:p.Y231C;VariantGroup:2;CorrespondingGene:5664;RS#:200754713;CorrespondingSpecies:9606;CA#:1424612
39273625	1106	1115	Ile235Phe	ProteinMutation	tmVar:p|SUB|I|235|F;HGVS:p.I235F;VariantGroup:4;CorrespondingGene:5664;CorrespondingSpecies:9606
39273625	1117	1126	Ala237Val	ProteinMutation	tmVar:p|SUB|A|237|V;HGVS:p.A237V;VariantGroup:0;CorrespondingGene:5664;RS#:200670135;CorrespondingSpecies:9606;CA#:237505
39273625	1128	1137	Leu238Phe	ProteinMutation	tmVar:p|SUB|L|238|F;HGVS:p.L238F;VariantGroup:1;CorrespondingGene:5664;RS#:367855127;CorrespondingSpecies:9606;CA#:1424616
39273625	1139	1148	Leu238Pro	ProteinMutation	tmVar:p|SUB|L|238|P;HGVS:p.L238P;VariantGroup:6;CorrespondingGene:5664;RS#:1211631545;CorrespondingSpecies:9606
39273625	1154	1163	Met239Thr	ProteinMutation	tmVar:p|SUB|M|239|T;HGVS:p.M239T;VariantGroup:5;CorrespondingGene:5664;CorrespondingSpecies:9606
39273625	1236	1241	PSEN2	Gene	5664
39273625	1295	1300	Abeta	Gene	351
39273625	1429	1434	Abeta	Gene	351
39273625	1474	1481	patient	Species	9606
39273625	1491	1500	Val226Ala	ProteinMutation	tmVar:p|SUB|V|226|A;HGVS:p.V226A;VariantGroup:3;CorrespondingGene:5664;RS#:1408884573;CorrespondingSpecies:9606
39273625	1542	1556	hallucinations	Disease	MESH:D006212
39273625	1561	1579	memory dysfunction	Disease	MESH:D008569
39273625	1615	1629	hallucinations	Disease	MESH:D006212
39273625	1633	1635	AD	Disease	MESH:D000544
39273625	1672	1677	PSEN2	Gene	5664
39273625	1731	1747	Notch Receptor 3	Gene	4854
39273625	1749	1755	NOTCH3	Gene	4854
39273625	1760	1785	Glucosylceramidase Beta-1	Gene	2629
39273625	1787	1790	GBA	Gene	2629
39273625	1830	1844	hallucinations	Disease	MESH:D006212
39273625	1892	1897	PSEN2	Gene	5664
39273625	1898	1907	Val226Ala	ProteinMutation	tmVar:p|SUB|V|226|A;HGVS:p.V226A;VariantGroup:3;CorrespondingGene:5664;RS#:1408884573;CorrespondingSpecies:9606
39273625	1911	1913	AD	Disease	MESH:D000544
39273625	Association	MESH:D000544	5664
39273625	Association	2629	5664
39273625	Positive_Correlation	MESH:D006212	RS#:1408884573;HGVS:p.V226A;CorrespondingGene:5664
39273625	Association	MESH:D000544	RS#:367855127;HGVS:p.L238F;CorrespondingGene:5664
39273625	Association	MESH:D000544	RS#:1408884573;HGVS:p.V226A;CorrespondingGene:5664
39273625	Positive_Correlation	MESH:D008569	RS#:1408884573;HGVS:p.V226A;CorrespondingGene:5664
39273625	Association	MESH:D000544	HGVS:p.M239T;CorrespondingGene:5664
39273625	Association	MESH:D006212	5664
39273625	Association	MESH:D008569	5664
39273625	Association	4854	5664

